Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy

被引:8
|
作者
Serfling, Sebastian E. [1 ]
Hartrampf, Philipp E. [1 ]
Zhi, Yingjun [2 ]
Higuchi, Takahiro [1 ,3 ]
Rowe, Steven P. [4 ]
Bundschuh, Lena [5 ]
Essler, Markus [5 ]
Buck, Andreas K. [1 ]
Bundschuh, Ralph Alexander [5 ]
Werner, Rudolf A. [1 ,4 ]
机构
[1] Julius Maximilian Univ Wurzburg, Dept Nucl Med, Univ Hosp Wurzburg, Wurzburg, Germany
[2] Julius Maximilian Univ Wurzburg, Dept Otorhinolaryngol Aesthet & Reconstruct Head, Wurzburg, Germany
[3] Okayama Univ, Fac Med Dent & Pharmaceut Sci, Okayama, Japan
[4] Johns Hopkins Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA
[5] Univ Hosp Bonn, Dept Nucl Med, Venusberg Campus 1, D-53127 Bonn, Germany
基金
日本学术振兴会;
关键词
fibroblast activation protein inhibitor; FAPI; molecular imaging; theranostics; endoradiotherapy; RADS; CANCER; CLASSIFICATION;
D O I
10.1097/RLU.0000000000004189
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives Fibroblast activation protein (FAP) has emerged as a novel target for FAP inhibitor (FAPI)-directed molecular imaging and endoradiotherapy (ERT). We aimed to assess the interobserver agreement rates for interpretation of Ga-68-FAPI-4 PET/CT and decision for ERT. Patients and Methods A random order of Ga-68-FAPI-4 PET/CTs from 49 oncology patients were independently interpreted by 4 blinded readers. Per scan, visual assessment was performed, including overall scan impression, number of organ/lymph node (LN) metastases, and number of affected organs/LN regions. Moreover, a maximum of 3 target lesions, defined as largest in size and/or most intense, per organ compartment were identified, which allowed for an additional quantitative interobserver assessment of LN and organ lesions. To investigate potential reference tissues, quantification also included unaffected liver parenchyma and blood pool. Readers also had to indicate whether FAPI-directed ERT should be considered (based on intensity of uptake and widespread disease). Interobserver agreement rates were evaluated using intraclass correlation coefficients (ICCs) and interpreted according to Cicchetti (with 0.4-0.59 indicating fair, and 0.6-0.74 good, agreement). Results On a visual basis, the agreement rate for an overall scan impression was fair (ICC, 0.42; 95% confidence interval [CI], 0.27-0.57). The concordance rate for number of affected LN areas was also fair (ICC, 0.59; 95% CI, 0.45-0.72), whereas the number of LN metastases, number of affected organs, and number of organ metastases achieved good agreement rates (ICC, >= 0.63). In a quantitative analysis, concordance rates for LN were good (ICC, 0.70; 0.48-0.88), but only fair for organ lesions (ICC, 0.43; 0.26-0.60). In regards to background tissues, ICCs were good for unaffected liver parenchyma (0.68; 0.54-0.79) and fair for blood pool (0.43; 0.29-0.58). When readers should decide on ERT, concordance rates were also fair (ICC, 0.59; 95% CI, 0.46-0.73). Conclusions For FAPI-directed molecular imaging and therapy, a fair to good interobserver agreement rate was achieved, supporting the adoption of this radiotracer for clinical routine and multicenter trials.
引用
收藏
页码:512 / 516
页数:5
相关论文
共 50 条
  • [41] Molecular Imaging of Fibroblast Activation in Rabbit Atherosclerotic Plaques: a Preclinical PET/CT Study
    Ji, Tianxiong
    Zan, Chunfang
    Li, Lina
    Cao, Jianbo
    Su, Yao
    Wang, Hongliang
    Wu, Zhifang
    Yang, Min-Fu
    Dou, Kefei
    Li, Sijin
    MOLECULAR IMAGING AND BIOLOGY, 2024, 26 (04) : 680 - 692
  • [42] Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine
    Aso, Ayaka
    Nabetani, Hinako
    Matsuura, Yoshifumi
    Kadonaga, Yuichiro
    Shirakami, Yoshifumi
    Watabe, Tadashi
    Yoshiya, Taku
    Mochizuki, Masayoshi
    Ooe, Kazuhiro
    Kawakami, Atsuko
    Jinno, Naoya
    Toyoshima, Atsushi
    Haba, Hiromitsu
    Wang, Yang
    Cardinale, Jens
    Giesel, Frederik Lars
    Shimoyama, Atsushi
    Kaneda-Nakashima, Kazuko
    Fukase, Koichi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (10)
  • [43] Development of ibuprofen-modified fibroblast activation protein radioligands to improve cancer therapy
    Zhou, Hui
    Zhong, Jiawei
    Liu, Yang
    Peng, Simin
    Yan, Qingsong
    Wang, Lijuan
    Zhong, Yuhua
    Hu, Kongzhen
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 283
  • [44] Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond
    Younis, Muhsin H.
    Malih, Sara
    Lan, Xiaoli
    Rasaee, Mohammad Javad
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (06) : 1773 - 1777
  • [45] Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy
    Fang, Qi
    Liu, Shaoyu
    Cui, Jiangyu
    Zhao, Ruiyue
    Han, Qian
    Hou, Peng
    Li, Youcai
    Lv, Jie
    Zhang, Xiaoyao
    Luo, Qun
    Wang, Xinlu
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2022, 10
  • [46] Intense fibroblast activation protein inhibitor localization around the site of embolized gastroduodenal artery in a patient with metachronous pancreatic adenocarcinoma: A potential pitfall in positron imaging
    Abdlkadir, Ahmed Saad
    Alalawi, Hasan
    Al-Ibraheem, Akram
    ACTA RADIOLOGICA OPEN, 2024, 13 (12)
  • [47] Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor
    Toms, Johannes
    Kogler, Juergen
    Maschauer, Simone
    Daniel, Christoph
    Schmidkonz, Christian
    Kuwert, Torsten
    Prante, Olaf
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (12) : 1806 - 1813
  • [48] 86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis
    Ding, Jie
    Xu, Mengxin
    Chen, Junyi
    Zhang, Pu
    Huo, Li
    Kong, Ziren
    Liu, Zhibo
    MOLECULAR PHARMACEUTICS, 2022, 19 (09) : 3429 - 3438
  • [49] 177Lu Radiolabeled Polydopamine Decorated with Fibroblast Activation Protein Inhibitor for Locoregional Treatment of Glioma
    Wang, Yadong
    Qiu, Long
    Ye, Tianzhen
    Tan, Fuyuan
    Lyu, Jie
    Li, Feize
    Sun, Zhizhong
    Yang, Yuanyou
    Zhang, Jinsong
    Liu, Ning
    Liao, Jiali
    CHEMBIOCHEM, 2025, 26 (03)
  • [50] Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor PET in a Human-Sized Swine Model
    Pirasteh, Ali
    Periyasamy, Sarvesh
    Meudt, Jennifer Jean
    Liu, Yongjun
    Lee, Laura M.
    Schachtschneider, Kyle M.
    Schook, Lawrence B.
    Gaba, Ron C.
    Mao, Lu
    Said, Adnan
    McMillan, Alan Blair
    Laeseke, Paul F.
    Shanmuganayagam, Dhanansaya
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (12) : 1956 - 1961